ArriVent BioPharma (AVBP) Q2 2024 earnings summary

Executive summary

• Clinical-stage biopharma focused on oncology, with lead candidate firmonertinib in multiple trials for EGFR-mutant NSCLC, including a pivotal Phase 3 study and clinical proof-of-concept data to be presented at WCLC 2024; received FDA Breakthrough Therapy and Orphan Drug Designations.

• Entered multi-target ADC collaboration with Alphamab, expanding the oncology pipeline.

• Strengthened board with appointments of John Hohneker, M.D. and Kristine Peterson, both with extensive biopharma leadership experience.

• No products approved or revenue generated; operations funded by private placements and a $183.2M IPO in January 2024, with all preferred stock converting to common shares.

• Net loss increased to $39.3M for the six months ended June 30, 2024, compared to $33.7M in the prior year period, driven by higher R&D and G&A expenses.

Financial highlights

• Cash and cash equivalents were $298.7M as of June 30, 2024, up from $150.4M at year-end 2023, expected to fund operations into 2026.

• Six-month operating expenses rose to $46.4M from $34.8M year-over-year, with R&D at $38.8M and G&A at $7.6M.

• Net cash used in operations was $37.7M for the six months ended June 30, 2024, up from $25.5M in the prior year period.

• Interest income increased to $7.1M for the six months, reflecting higher balances and yields.

• Net loss per share for the six months was $(1.34), compared to $(20.60) in the prior year, reflecting increased share count post-IPO.

Outlook and guidance

• Cash runway expected to fund operations into 2026, but future capital needs depend on clinical progress, regulatory outcomes, and potential commercialization.

• Interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC to be presented at WCLC 2024, with a webinar scheduled for September 9, 2024.

• Selection of next-generation ADC clinical candidate expected in late 2024 or early 2025.

• Top-line pivotal Phase 3 data for firmonertinib in EGFR exon 20 insertion mutant NSCLC anticipated in 2025.

• Anticipates continued and increasing operating losses as R&D and pipeline investments accelerate.